Celgene Corporation (CELG) : Morgens Waterfall Vintiadis Co Inc scooped up 30,000 additional shares in Celgene Corporation during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Jul 21, 2016. The investment management firm now holds a total of 56,000 shares of Celgene Corporation which is valued at $6,021,120.Celgene Corporation makes up approximately 5.89% of Morgens Waterfall Vintiadis Co Inc’s portfolio.
Other Hedge Funds, Including , Dowling Yahnke boosted its stake in CELG in the latest quarter, The investment management firm added 3,122 additional shares and now holds a total of 24,686 shares of Celgene Corporation which is valued at $2,654,239. Celgene Corporation makes up approx 0.31% of Dowling Yahnke’s portfolio.Rockefeller Financial Services Inc reduced its stake in CELG by selling 300 shares or 1.93% in the most recent quarter. The Hedge Fund company now holds 15,269 shares of CELG which is valued at $1,641,723. Celgene Corporation makes up approx 0.03% of Rockefeller Financial Services Inc’s portfolio.Bkd Wealth Advisors boosted its stake in CELG in the latest quarter, The investment management firm added 3 additional shares and now holds a total of 3,098 shares of Celgene Corporation which is valued at $315,252. Celgene Corporation makes up approx 0.05% of Bkd Wealth Advisors’s portfolio.Chevy Chase Trust Holdings boosted its stake in CELG in the latest quarter, The investment management firm added 2,392 additional shares and now holds a total of 693,691 shares of Celgene Corporation which is valued at $72,858,366. Celgene Corporation makes up approx 0.40% of Chevy Chase Trust Holdings’s portfolio.
Celgene Corporation opened for trading at $109.91 and hit $112.25 on the upside on Thursday, eventually ending the session at $111.26, with a gain of 2.91% or 3.15 points. The heightened volatility saw the trading volume jump to 83,30,698 shares. Company has a market cap of $86,182 M.
On the company’s financial health, Celgene Corporation reported $1.32 EPS for the quarter, beating the analyst consensus estimate by $ 0.05 according to the earnings call on Apr 28, 2016. Analyst had a consensus of $1.27. The company had revenue of $2511.60 million for the quarter, compared to analysts expectations of $2577.08 million. The company’s revenue was up 20.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.07 EPS.
Many Wall Street Analysts have commented on Celgene Corporation. Stifel Initiated Celgene Corporation on Jul 15, 2016 to “Buy”, Price Target of the shares are set at $138.Company shares were Reiterated by Sun Trust Rbsn Humphrey on Apr 29, 2016 to “Buy”, Firm has raised the Price Target to $ 147 from a previous price target of $145 .
Celgene Corporation (Celgene) together with its subsidiaries is an integrated biopharmaceutical company engaged primarily in the discovery development and commercialization of therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. The Companys primary commercial stage products include REVLIMID (lenalidomide) ABRAXANE POMALYST/IMNOVID VIDAZA azacitidine for injection (generic version of VIDAZA) THALOMID (sold as THALOMID or Thalidomide Celgene outside the United States) OTEZLA (apremilast) and ISTODAX (romidepsin). Celgene is involved in research in a range of scientific areas designed to deliver therapies targeting areas including intracellular signaling pathways protein homeostasis and epigenetics in cancer and immune cells immunomodulation in cancer and autoimmune diseases and therapeutic application of cell therapies.